Sinovac Announces Results of 2016 Annual General Meeting of Shareholders BEIJING

Sinovac Announces Results of 2016 Annual

General Meeting of Shareholders

BEIJING, November 7, 2016 /PRNewswire/

-- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results

of the Company's 2016 Annual General Meeting of Shareholders held on Monday, November 7, 2016 in Beijing, PRC. The

required quorum, a majority of the common shares outstanding, was voted by proxy.

The Company's shareholders approved the following

Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization

of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and

B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac

was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's

vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the

government stockpiling program. Sinovac's newly developed innovative vaccine against HFMD caused by EV71 is ready for market launch.

The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides

vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring

growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, Tajikistan,

Bangladesh, Chile and the Philippines, and was recently granted a license to commercialize its influenza vaccine in Guatemala.

For more information, please visit the Company's website at www.sinovac.com.